Business Context and Reporting Period
This Form 8-K Current Report was filed by Quince Therapeutics, Inc. (QNCX) on July 29, 2026. The filing discloses significant changes in executive leadership and board composition contingent upon the approval of specific stockholder proposals at a Special Meeting anticipated for September 25, 2026.
Key Financial Metrics
The filing text does not provide specific financial data regarding revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance and personnel changes.
Material Changes
Executive Departures
- Dirk Thye: Chief Executive Officer, Chief Medical Officer, and Board Director tendered a conditional resignation effective two business days after the Special Meeting.
- Brendan Hannah: Chief Operating Officer, Chief Business Officer, and Chief Compliance Officer tendered a conditional resignation effective two business days after the Special Meeting.
- Conditions: Resignations are contingent upon stockholder approval of the Conversion Proposal, Minimum Price Proposal, and Authorized Share Proposal.
- Compensation: Both executives remain entitled to previously disclosed retention bonuses and severance amounts if they remain employed through the Special Meeting date.
Executive Appointments
- Brigette Roberts, M.D.: Conditionally appointed as Chief Executive Officer and Principal Executive Officer.
- John Militello, CPA: Conditionally appointed as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer.
- Keith R. Fandrick, Ph.D.: Conditionally appointed as Chief Operating Officer.
Board Composition
The Board size will be reduced from five to four directors immediately upon the effectiveness of Dirk Thye's resignation. The Board intends to appoint an independent director in the future.
Guidance, Outlook, and Risks
The filing outlines three critical stockholder proposals required for the leadership transition to occur:
- Conversion Proposal: Approval for issuing common stock upon conversion of Series C Preferred Stock and exercise of warrants related to the acquisition of Orphai Holdings Therapeutics, Inc. and a concurrent private placement (PIPE).
- Minimum Price Proposal: Approval for issuing common stock upon conversion of Series C Preferred Stock and exercise of warrants issued to PIPE investors under Nasdaq Listing Rule 5635(d).
- Authorized Share Proposal: Amendment to increase authorized common stock from 250,000,000 to 275,000,000 shares.
Risk: The leadership changes are not immediate and depend entirely on the outcome of the September 25, 2026, Special Meeting.
Investor Verification Checklist
- Verify the outcome of the Special Meeting of Stockholders scheduled for September 25, 2026.
- Review the Preliminary Proxy Statement (Schedule 14A) filed on July 31, 2026, for details on the Conversion, Minimum Price, and Authorized Share proposals.
- Confirm the final effective date of the executive resignations and appointments based on the Special Meeting results.
- Monitor for the appointment of a new independent director to fill the vacancy on the Board.